Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | PTGES | O14684 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914592 | 0.88 | ALOX12 (0.39) | HRH3PTGESKDM1AKCNH2ACACB | |
| SCHEMBL3578255 | 0.73 | PTGES (0.69) | ALDH1A1TSHRHRH3PTGESACACB | |
| SCHEMBL4923166 | 0.72 | EPHX2 (0.39) | ALDH1A1TSHRHRH3PTGESSMN1; SMN2 | |
| SCHEMBL3569096 | 0.72 | PTGES (0.43) | ALDH1A1TSHRHRH3PTGESEPHX2 | |
| SCHEMBL5269897 | 0.71 | MAP2 (0.50) | ALDH1A1 | |
| SCHEMBL4095900 | 0.70 | EPHX2 (0.39) | PTGESKCNH2EPHX2ACACB | |
| SCHEMBL3574897 | 0.70 | PTGES (0.40) | ALDH1A1TSHRHRH3PTGESKCNH2 | |
| SCHEMBL4087011 | 0.70 | EPHX2 (0.38) | EPHX2FFAR1ACACB | |
| SCHEMBL4697234 | 0.69 | MAP4K4 (0.53) | ALDH1A1TSHRPTGESKCNH2EPHX2 | |
| SCHEMBL3576474 | 0.69 | PTGES (0.71) | ALDH1A1TSHRHRH3PTGESSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | ALDH1A1 2274/4885TSHR 1248/4885HRH3 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.